Physician
Infectious Disease
Dr. Mark P. Eggena, MD
|
|
Give Review
Dr. Mark P. Eggena is an expert in the field of Infectious Disease. He studied medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. He received 2 awards: "Regional Top Doctor" and "Diabetes Recognition Program". Dr. Mark P. Eggena is also a published doctor. He has 14 publication published. The most recent publication is: pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis. He is registered with Medicare.
Publications
- CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
- Depletion of regulatory T cells in HIV infection is associated with immune activation.
- T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.
- Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen.
- Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.
- Definition of ocular antigens in ciliary body and retinal ganglion cells by the marker antibody pANCA.
- Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with C...
- Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies.
- Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection.
- Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA.
- Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo.
- Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis.
- pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.
Schools
University of California At Los Angeles
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Regional Top Doctor
- Diabetes Recognition Program
Education
-
UCSF -
David Geffen School of Medicine at UCLA
Drug Facts
| NPI NUMBER | 1235108580 | |
| NPPES Provider LastName | EGGENA | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 04856 | |
| NPPES Provider State | ME | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 3264.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 186.0 | |
| Percent Opioid Claims | 5.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235108580 |
| Last Name Of The Provider | EGGENA |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Robert L. Pinsky, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice M. Savage, MD |
|
|
Dr. Nancy Epifano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl A. Liechty, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|